You are here:  Home     October 22, 2014


National Pediatric Sleep Groups   
News and activities from Pediatric Sleep Groups all over the world

Pediatric Sleep


IPSA suggestions   
help us to make IPSA more complete and useful, send information about pediatric sleep activities in Your country.

IPSA Congress 2014 - Porto Alegre - Brazil - Sunday, September 29, 2013

It is my pleasure to present the
III Congress of the International Pediatric Sleep Association (IPSA) - Porto Alegre (Brazil) 3-5 December 2014.

The importance of sleep for health, learning and psychomotor development in infancy, childhood and adolescence has been emphasized in the pediatric research in the last two decades and it has become more and more evident that ensuring a good sleep during development is of key importance for a later healthy life.
The IPSA Congress is an influential forum for sleep practitioners from around the world to network and exchange views, whilst learning from world-class researchers about the latest scientific and clinical developments in the field.
The success of the last two Congresses in Rome 2010 and Manchester 2012 has highlighted the magnitude of Pediatric Sleep Medicine in the scientific community and we hope that the 2014 Congress will provide a perfect balance between didactic and practical needs, in order to provide the technical knowhow and up-to-date knowledge that will enable participants to improve their practice.
As traditional for IPSA, the most renowned International opinion leaders in the field of Pediatric Sleep Medicine speakers will join the Congress and will highlight the recent significant advances in both basic science and clinical sleep medicine during development.
I hope that the world paediatric sleep community will gather together in the lively city of Porto Alegre to celebrate the best clinical practice and the latest advances in Pediatric Sleep Medicine.

Oliviero Bruni
President of the International Pediatric Sleep Association


IPSA Congress 5-7 december 2012 - Manchester City (UK)

IPSA Congress 5-7th December 2012 - Manchester (UK)  


IPSA 2010 - Abstract Book




Guia SAOS Infantil Espanola

New guidelines on the diagnosis and treatment of OSA in children published by the Spanish Pediatric Sleep Group. (available only in Spanish)



[PageLinks]     TIP: Press shift while clicking on the article to open in a new window.

Preservation of microelectrode recordings with non-GABAergic drugs during deep brain stimulator placement in children.
Related Articles

Preservation of microelectrode recordings with non-GABAergic drugs during deep brain stimulator placement in children.

J Neurosurg Pediatr. 2014 Sep;14(3):279-86

Authors: Hippard HK, Watcha M, Stocco AJ, Curry D

OBJECT: Deep brain stimulation (DBS) has become accepted therapy for intractable dystonia and other movement disorders. The accurate placement of DBS electrodes into the globus pallidus internus is assisted by unimpaired microelectrode recordings (MERs). Many anesthetic and sedative drugs interfere with MERs, requiring the patient to be awake for target localization and neurological testing during the procedure. In this study, a novel anesthetic technique was investigated in pediatric DBS to preserve MERs.
METHODS: In this paper, the authors describe a sedative/anesthetic technique using ketamine, remifentanil, dexmedetomidine, and nicardipine in 6 pediatric patients, in whom the avoidance of GABAergic stimulating drugs permitted excellent surgical conditions with no detrimental effects on intraoperative MERs. The quality of the MERs, and the frequency of its use in making electrode placement decisions, was reviewed.
RESULTS: All 6 patients had good-quality MERs. The data were of sufficient quality to make a total of 9 trajectory adjustments.
CONCLUSIONS: Microelectrode recordings in pediatric DBS can be preserved with a combination of dexmedetomidine and ketamine, remifentanil, and nicardipine. This preservation of MERs is particularly crucial in electrode placement in children.

PMID: 24995822 [PubMed - indexed for MEDLINE]

Immune profiling of pregnant Toxoplasma-infected US and Colombia patients reveals surprising impacts of infection on peripheral blood cytokines.
Related Articles

Immune profiling of pregnant Toxoplasma-infected US and Colombia patients reveals surprising impacts of infection on peripheral blood cytokines.

J Infect Dis. 2014 Sep 15;210(6):923-31

Authors: Pernas L, Ramirez R, Holmes TH, Montoya JG, Boothroyd JC

In North America (NA) and Europe, the majority of toxoplasmosis cases are benign and generally asymptomatic, whereas in South America (SA) toxoplasmosis is associated with much more severe symptoms in adults and congenitally infected children. The reasons for these differences remain unknown; currently, there is little information from patients in either region on how the immune system responds to infection with Toxoplasma gondii. Here, we report the relative abundance of 51 serum cytokines from acute and chronic toxoplasmosis cohorts of pregnant women from the United States, where approximately one-half of clinical isolates are Type II, and Colombia, where clinical isolates are generally "atypical" or Type I-like strains. Surprisingly, the results showed notably lower levels of 23 cytokines in acutely infected patients from the United States, relative to uninfected US controls. In acutely infected Colombian patients, however, only 8 cytokine levels differed detectably with 4 being lower and 4 higher relative to uninfected controls. Strikingly, there were also differences in the cytokine profiles of the chronically infected patients relative to uninfected controls in the US cohort. Hence, Toxoplasma appears to specifically impact levels of circulating cytokines, and our results may partly explain region-specific differences in the clinical spectrum of toxoplasmosis.

PMID: 24664173 [PubMed - indexed for MEDLINE]


Join IPSA. It's free!!!   
Just add Your data to the membership module  

Upcoming Meetings   


Home|IPSA Mission|Board|Bylaws|Contact IPSA|Membership|Site Map
Copyright (c) 2014 IPSA Terms Of Use Privacy Statement